This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
RedHill Files CTA for Coronavirus Study on Opaganib in Russia
by Zacks Equity Research
RedHill (RDHL) submits a Clinical Trial Application in Russia for a phase II/III study on opaganib to treat patients detected with severe COVID-19 infection and pneumonia. Stock up.
Lilly Begins Cardiovascular Outcomes Study on Tirzepatide
by Zacks Equity Research
Lilly (LLY) announces that the first patient dose has been delivered in a cardiovascular outcome study on its novel diabetes candidate, tirzepatide.
Sanofi (SNY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Sanofi (SNY) closed at $50.85 in the latest trading session, marking a +0.08% move from the prior day.
The Zacks Analyst Blog Highlights: Mastercard, Novartis, Boeing Company, Sanofi and Honeywell International
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Mastercard, Novartis, Boeing Company, Sanofi and Honeywell International
This is Why Sanofi (SNY) is a Great Dividend Stock
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Sanofi (SNY) have what it takes? Let's find out.
AbbVie (ABBV) Joins Race for Developing Coronavirus Treatment
by Zacks Equity Research
AbbVie (ABBV) collaborates with three parties for developing an antibody-based treatment for COVID-19.
Alnylam Reports Positive Phase III Results on Lumasarin
by Zacks Equity Research
Alnylam (ALNY) reports positive phase III results from the ILLUMINATE-A study on lumasiran.
Top Stock Reports for Mastercard, Novartis & Boeing
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Mastercard (MA), Novartis (NVS) and Boeing Company (BA).
Lilly Begins Coronavirus Study to Evaluate Antibody Therapy
by Zacks Equity Research
Lilly (LLY) initiates dosing in a phase I study to evaluate an antibody candidate for treating COVID-19.
Regeneron Expands Deal With Intellia for Hemophilia Treatments
by Zacks Equity Research
Regeneron (REGN) expands partnership with Intellia Therapeutics to co-develop potential hemophilia A and B treatments.
The Zacks Analyst Blog Highlights: Merck, Glaxo, Roche, Sanofi and Bristol-Myers
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Merck, Glaxo, Roche, Sanofi and Bristol-Myers
Glaxo Plans to Make 1B Doses of Coronavirus Vaccine Adjuvant
by Zacks Equity Research
Glaxo (GSK) set to enhance its manufacturing capacity to make 1 billion doses of its pandemic vaccine adjuvant, which can be used to improve efficacy and scale up of multiple COVID-19 vaccines.
Protalix Submits BLA for Fabry Disease Candidate PRX-102
by Zacks Equity Research
Protalix (PLX) announces submission of regulatory application seeking approval for its lead pipeline candidate, pegunigalsidase alfa, for Fabry disease.
Pharma Stock Roundup: MRK, RHHBY Give Coronavirus Updates,SNY to Sell Stake in REGN
by Kinjel Shah
Merck (MRK), Glaxo (GSK) and Roche (RHHBY) make progress in coronavirus research efforts.
Sanofi's Dupixent Gets FDA Approval for Eczema in Children
by Zacks.com
Sanofi (SNY) secures an FDA nod for Dupixent as the first biologic medicine for children aged from six to 11 years with moderate-to-severe atopic dermatitis.
Race for Coronavirus Vaccine Heats Up: Biotech ETFs to Gain
by Sweta Killa
The COVID-19 pandemic has kept biotech players all over the world on their toes for a vaccine. This new opportunity has made the sector the most attractive one to investors.
Biotech Stock Roundup: REGN's Stake Buyback, INO, NVAX's Coronavirus Updates & More
by Zacks Equity Research
The biotech sector remains in focus with updates on coronavirus treatments and other pipeline updates.
Alnylam's (ALNY) Lumasiran NDA Gets Priority Review From FDA
by Zacks Equity Research
Alnylam's (ALNY) NDA seeking approval for lumasiran for treating kidney disease, primary hyperoxaluria type 1, gets priority review from the FDA.
Merck Inks 3 Deals for Coronavirus Anti-infective & Vaccines
by Zacks Equity Research
Merck (MRK) to buy Themis, which is making a COVID-19 vaccine. It is also buying global rights to a private biotech's antiviral candidate, EIDD-2801, which is in early clinical studies to treat COVID-19.
The Zacks Analyst Blog Highlights: Moderna, Pfizer, BioNTech, Sanofi and GlaxoSmithKline
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Moderna, Pfizer, BioNTech, Sanofi and GlaxoSmithKline
Regeneron (REGN) to Buy Back Part of Its Stake Held by Sanofi
by Zacks Equity Research
Regeneron (REGN) commences underwritten public secondary offering of its common stock held by Sanofi and repurchases shares for $5 billion.
Sanofi to Sell Stake in Regeneron, Existing Deal Unchanged
by Zacks Equity Research
Sanofi (SNY) intends to sell majority of its shareholding in its collaboration partner, Regeneron. However, there will be no change in the ongoing collaboration terms.
Coronavirus Vaccine Development Gathers Steam: 4 Winners
by Ritujay Ghosh
Many biotech companies are coming up with impressive reports on their development of drugs, vaccines and therapies for COVID-19.
Coronavirus Vaccine Race Pushes Up Pharma Giants' Production
by Ritujay Ghosh
Biotech companies and drugmakers are speeding up development of a vaccine for COVID-19. This has seen many big players joining forces to come up with a treatment.
Why Sanofi (SNY) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Sanofi (SNY) have what it takes? Let's find out.